Novartis has provided updated data from phase 3 trials of ZOLGENSMA (onasemnogene abeparvovec-xioi) for patients with spinal muscular atrophy. …
Latest Video
New Stories
-
Companies already contemplating the risk of 'Pelosi plan'
October 18, 2019 - - Latest News -
Gilead: Elimination 'in reach' but more work required
October 18, 2019 - - Latest News -
Baby boom at Mundipharma in response to policy change
October 18, 2019 - - Latest News -
Bayer backs program targeting physical health in rural Australia
October 18, 2019 - - Latest News -
Patients welcome new action plan for osteoporosis
October 18, 2019 - - Latest News -
Pricing proposal will 'destroy' the industry and halve drug approvals
October 17, 2019 - - Latest News -
US proposal a 'game over' moment for Australian access
October 17, 2019 - - Comment